NAUTNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Nautilus Biotechnology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026
$2.63+0.57 (+27.67%)
Close on Oct 19, 2026
- Market cap
- $334.37M
- P/E (TTM)
- –
- Dividend yield
- –
Nautilus Biotechnology, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q2 25 | % of revenue | YoY |
|---|---|---|---|---|
| Grant revenue | $180.00K | $0 | 94.7% | – |
| Service revenue | $10.00K | $0 | 5.3% | – |
By region
From the segment and revenue-disaggregation notes of Nautilus Biotechnology's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.